Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
EMEA Recommends Orphan Drug Designation for AX200 for the Treatment of Amyotrophic Lateral Sclerosis
February 29th, 2008
SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard), announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) for AX200 for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive neurodegenerative disease caused by the degeneration of nerve cells innervating skeletal muscles and affects an estimated 50,000 to 100,000 people in the industrialized nations. Patients with ALS suffer from progressive muscle wasting throughout their bodies resulting in increasing disabilities and their lifespan is cut short. Death in ALS patients normally occurs...
Source: Health Business Week (2008-02-29)
|
